Journals / European Journal of Rheumatology / 2014 / Cilt: 1 - Sayı: 4

A case of neutrophilic dermatosis who develop palpable purpura during the use of montelukast

Pages
170–171
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It is important that this is the first case report

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this case report, we present a female patient with neutrophilic dermatosis (ND) occurring as palpable purpura after using montelukast.
📊
Key Findings & Data:Neutrophilic dermatoses (NDs) are characterized by skin lesions in which mature neutrophils are predominantly located in the epidermis and dermis in the absence of any infective pathology.
💡
Conclusion & Impact:It is important that this is the first case report
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In this case report, we present a female patient with neutrophilic dermatosis (ND) occurring as palpable purpura after using montelukast. Neutrophilic dermatoses (NDs) are characterized by skin lesions in which mature neutrophils are predominantly located in the epidermis and dermis in the absence of any infective pathology. Classification of the NDs is based upon the recognition of clinical and pathologic features, as well as the identification of associated diseases, like Sweet's syndrome, pyoderma gangrenosum, generalized pustular psoriasis, and Behçet's disease. Cutaneous findings in NDs are variable and can include vesiculopustules, plaques, nodules, or ulcerations. Drug-induced NDs are not uncommon, but ND with palpable purpura is uncommon. The current patient appeared with a rare presentation as palpable purpura without vasculitis regarding ND. It is important that this is the first case report

🔖

Cite This Article

CIRALIK, H., SAYARLIOĞLU, H., ERHAN, Ç., ÇETİN, G. Y., SAYARLIOĞLU, M., KAHRAMAN, H. (2022). A case of neutrophilic dermatosis who develop palpable purpura during the use of montelukast. European Journal of Rheumatology, Cilt: 1 - Sayı: 4, 170–171. https://ajindex.com/articles/511846

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculi- tides. Proposal of an international consensus con- ference. Arthritis Rheum 1994; 37: 187. [CrossRef] Fett N, Callen J, Ofori AO. Evaluation of adults with cutaneous lesions of vasculitis. UpToDate. 2014. Available from: www.uptodate.com Sweet RD. An acute febrile neutrophilic derma- tosis. Br J Dermatol 1964; 76: 349-56. [CrossRef] 4. Nischal KC, Khopkar U. An approach to the diagno- sis of neutrophilic dermatoses: A histopathological perspective. Indian Journal of Dermatology, Vene- reology and Leprology. 2007; 73: 222-30. [CrossRef] Moschella SL, Callen J, Ofori AO. Neutrophilic dermatoses. UpToDate. 2014. Available from: www.uptodate.com 6. Samel AD, Chu CY, Robert P, Dellavalle RP, Mocken- haupt M, Roujeau JC, et al. Drug eruptions. UpTo- Date. 2014. Available from: www.uptodate.com Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Phar- macol Ther 1981; 30: 239-45. [CrossRef] von den Driesch P. Sweet syndrome: Acute fe- brile neutrophilic dermatosis. J Am Acad Der- matol 1994; 31: 535-56. [CrossRef] Rochet NM, Chavan RN, Cappel MA, Wada DA, Gib- son LE. Sweet syndrome: clinical presentation, asso- ciations, and response to treatment in 77 patients. J Am Acad Dermatol 2013; 69: 557. [CrossRef] Coots NV, McCoy CE, Gehlbach DL, Becker LE. A neutrophilic drug reaction to Clomid. Cutis 1996; 57: 91-3. 171